<DOC>
	<DOCNO>NCT02353494</DOCNO>
	<brief_summary>This observational safety efficacy study dihydroartemisinin-piperaquine Timika , Indonesia 42 day follow period .</brief_summary>
	<brief_title>Efficacy Safety Dihydroartemisinin-piperaquine ( DHP ) Treatment Uncomplicated Malaria</brief_title>
	<detailed_description>Dihydroartemisinin-piperaquine ( DHA-Pip ) part current national guideline treatment uncomplicated malaria Indonesia . In order guarantee safe efficacious treatment patient diagnose uncomplicated malaria area , essential monitor effectiveness recommend treatment clinical perspective ass whether provide treatment safe recipient . This trial re-evaluates local efficacy safety DHA-Pip P. falciparum P. vivax infection . Patients uncomplicated malaria attend public health care facility Timika , Papua , Indonesia , meet study inclusion criterion enrol , treat site DHA-Pip follow 42 day . The follow-up consist fix schedule check-up visit correspond clinical laboratory examination . On basis result assessment , patient classify therapeutic failure ( early late ) adequate response . The proportion patient experience therapeutic failure drug relate adverse event follow-up period use estimate efficacy safety study drug . PCR analysis use distinguish true recrudescence due treatment failure episodes reinfection . The outcome propose project direct impact decision make process Indonesian Ministry Health whether need alter exist antimalarial treatment guideline .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Inclusion criterion : age one year ( weight 5 kg ) 65 year old ; monoinfection Plasmodium falciparum Plasmodium vivax detect microscopy ; parasitaemia 1000/μl asexual parasite P. falciparum 250/μl asexual parasite P. vivax presence axillary temperature ≥ 37.5 °C history fever past 24 h ; ability swallow oral medication ; ability willingness comply study protocol duration study comply study visit schedule ; inform consent patient parent guardian case child . Exclusion criterion : presence general danger sign child age 5 year sign severe falciparum malaria accord definition WHO mix monoinfection another Plasmodium specie detect microscopy ; presence severe malnutrition ( defined child whose growth standard 3 zscore , symmetrical oedema involve least foot midupper arm circumference &lt; 110 mm ) ; presence febrile condition due disease malaria ( e.g . measles , acute low respiratory tract infection , severe diarrhoea dehydration ) know underlie chronic severe disease ( e.g . cardiac , renal hepatic disease , HIV/AIDS ) ; regular medication , may interfere antimalarial pharmacokinetics ; history hypersensitivity reaction contraindication dihydroartemisininpiperaquine positive pregnancy test breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>